MIRODERM® Awarded Federal Supply Schedule Contract for Government Sales

Miromatrix Medical Inc., a biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products for soft tissue reinforcement and advanced wound care, announced today that they have been awarded a Federal Supply Schedule (FSS) contract to sell their product, MIRODERM® in all government facilities (e.g. VA Hospitals, DOD, etc.).  The MIRODERM family of products are acellular wound matrices derived from porcine liver and are intended for the management of wounds including: partial and full thickness wounds; venous and diabetic ulcers; surgical and trauma wounds, among others.  The earning of this contract adds MIRODERM to the existing contract that Miromatrix was awarded on December 1, 2016 for MIROMESH® (Contract Number V797D-70029). 

“With an FSS contract in place, we are excited to bring MIRODERM, our next-generation biologic wound matrix into the VA network of hospitals,” explained Jeff Ross, Ph.D., Chief Executive Officer of Miromatrix Medical.  “We are proud to be able to help the many veterans who serve our country.”

About Miromatrix:
Miromatrix Medical Inc. is a biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products such as MIROMESH® and MIRODERM® for soft tissue reinforcement and advanced wound care.  Miromatrix’ perfusion decellularization/recellularization technology is protected by a series of issued patents and pending patent applications in all major markets around the world. In addition to MIROMESH and MIRODERM, internal development programs at Miromatrix focus primarily on creating fully implantable human organs including livers, kidneys and heart products with collaborators including The Mayo Clinic, Texas Heart Institute and Mount Sinai Hospital, and aim at eliminating the organ transplant waiting list.